Unknown PHASE2 INTERVENTIONAL 2-arm NCT05077839

Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC (TOBACO)

Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer (TOBACO): a Randomized, Controlled, Phase II Study

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Conditions Advanced Colorectal Cancer First-line Treatment

Interventions Trifluridine/Tipiracil

Updated 4 times since 2021 Last updated: Oct 15, 2021 Started: Sep 1, 2021 Primary completion: Aug 31, 2024 Completion: Aug 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Colorectal Cancer and First-line Treatment and is currently ongoing. Tianjin Medical University Cancer Institute and Hospital leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Oct 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Oct 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Nov 2021 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Sep 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianjin Medical University Cancer Institute and Hospital

Data source: Tianjin Medical University Cancer Institute and Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China